NICE guidelines on cerebral palsy published

This guideline covers diagnosing, assessing and managing cerebral palsy in children and young people from birth up to their 25th birthday. It aims to make sure they get the care and treatment they need for the developmental and clinical comorbidities associated with cerebral palsy, so that they can be as active and independent as possible file File Name: nice_ng62_2017.pdf File Size: 180 kb Download File Recommendations This guideline includes recommendations on:  ​c auses and recognition o...
Continue reading

New treatment for Anti-NMDA receptor encephalitis

In a study have been published in the journal Neurology researchers from Charité - Universitätsmedizin Berlin and the German Center for Neurodegenerative Diseases (DZNE) using a new treatment regimen have recorded significant progress in patients with Anti-NMDA receptor encephalitis.  In addition to standard treatment, patients received bortezomib, a drug known as proteasome inhibitor that has proven successful in treating patients with plasmacytoma a haematological mali...
Continue reading

Systematic Review concludes Zika Virus as cause of birth defects and Guillain-Barre syndrome

Structure of the Zika Virus

A systematic review of the evidence confirms that infection with mosquito-borne Zika virus is a cause of Guillain-Barre Syndrome (GBS), in addition to microcephaly and other congenital brain abnormalities, according to a study published in PLOS Medicine by Nicola Low of the University of Bern, Switzerland, and colleagues in the World Health Organization (WHO) Zika Causality Working Group.  In March 2016, WHO stated that there was a strong scientific consensus that Zika virus is a cause...
Continue reading

ICNA Educational Meeting at the University of West Indies, Kingston, Jamaica Oct. 8, 2016

An ICNA educational satellite meeting which focused on six topics involving pediatric epilepsy, neuromuscular disorders and neurometabolic disorders was held Oct. 8, 2916 at the University of West Indies (UWI) in Kingston, Jamaica (details provided below). This was the first ICNA initiative in Jamaica. Our satellite was part of the 7th Biennial Conference of the Dept. of Child and Adolescent Health of the University of West Indies. Our team was very graciously received by our local hosts and our...
Continue reading

US FDA approves Nusinersen - The first treatment for SMA

The U.S. Food and Drug Administration (FDA) approved Biogen's SPINRAZA™ (nusinersen) under Priority Review for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. SPINRAZA (nusinersen) ​ is the first and only treatment approved in the U.S. for SMA. In ENDEAR, a pivotal controlled clinical study, infantile-onset SMA patients treated with nusinersen achieved and sustained clinically meaningful improvement in motor function compared to untreated study participants. In ad...
Continue reading